Quantcast
Home > Quotes > ATRA

Atara Biotherapeutics, Inc. Common Stock (ATRA) Quote & Summary Data

ATRA 
$37.21
*  
1.36
3.79%
Get ATRA Alerts
*Delayed - data as of Nov. 16, 2018  -  Find a broker to begin trading ATRA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ATRA Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
47.5
Today's High / Low
$ 37.64 / $ 35.18
Share Volume
1,046,677
50 Day Avg. Daily Volume
606,668
Previous Close
$ 35.85
52 Week High / Low
$ 54.45 / $ 13.20
Market Cap
1,698,571,978
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -4.64
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.77

Intraday Chart

Shares Traded

Share Volume:
1,046,677
50 Day Avg. Daily Volume:
606,668

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -4.64

Trading Range

The current last sale of $37.21 is 181.89% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 37.64 $ 54.45
 Low: $ 35.18 $ 13.20

Company Description (as filed with the SEC)

Atara Biotherapeutics is a leading T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. The Company's off-the-shelf, or allogeneic, T-cells are bioengineered from donors with healthy immune function and allow for rapid delivery from inventory to patients without a requirement for pretreatment. Atara's T-cell immunotherapies are designed to precisely recognize and eliminate cancerous or diseased cells without affecting normal, healthy cells. Atara's most advanced T-cell immunotherapy in development, tabelecleucel (formerly known as ATA129), is being developed for the treatment of patients with Epstein-Barr virus, or EBV, associated post-transplant lymphoproliferative disorder, or EBV+ PTLD, who have failed rituximab, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma, or NPC.  ... More ...  


Risk Grade

Where does ATRA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 35.42
Open Date:
Nov. 16, 2018
Close Price:
$ 35.85
Close Date:
Nov. 16, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x